|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 11400 Rockville Pike |
Address2 |
|
City | Rockville |
State | MD |
Zip Code | 20852 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401104864-12
|
||||||||
|
6. House ID# 440290001
|
TYPE OF REPORT | 8. Year | 2022 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Kelly Corredor |
Date | 10/18/2022 7:08:27 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ALC
16. Specific lobbying issues
Advocated for Increased appropriations for HRSAs Substance Use Disorder Treatment and Recovery Loan Repayment Program. This program provides student loan repayment for addiction treatment professionals who commit to working in underserved or high-risk communities.
Advocated for increased appropriations for HRSAs Addiction Medicine Fellowship Program. This program provides grants to institutions with training opportunities for fellows in addiction medicine and addiction psychiatry who have demonstrated interest in providing addiction treatment in underserved communities.
Advocated for S 2235/HR 2067 - Medication Access and Training Expansion (MATE) Act of 2021: This legislation would ensure most Drug Enforcement Agency (DEA) controlled medication prescribers have a baseline knowledge of how to identify, treat, and manage patients with SUD and would allow accredited health professional schools and residency programs to fulfill the training requirement through their own curricula, as well as provide them with resources to do so.
Advocated for simultaneous passage of S 445/HR 1384 - Mainstreaming Addiction Treatment (MAT) Act, which would eliminate the requirement that practitioners apply for a separate waiver through the DEA to prescribe buprenorphine for addiction and eliminate the patient limits on buprenorphine prescribers.
Advocated for S 285/HR 955 - the Medicaid Reentry Act: This legislation would allow for reestablishment of health insurance coverage under Medicaid for eligible individuals who
are incarcerated, during the 30-day period preceding their release from jail or prison.
Advocated for HR 1364/S.4804 - the Parity Enforcement Act: This legislation would expand the U.S. Department of Labors authority to hold health insurers and plan sponsors accountable for offering health plans that violate the Mental Health Parity and Addiction Equity Act (MHPAEA) of 2008 or for employing utilization review processes that prove more restrictive for mental health and addiction care than for other medical care in violation of the MHPAEA.
Advocated for S 340/HR 1674 - TREATS Act: This legislation would make permanent a new, audio-video, telehealth evaluation exception to the Ryan Haight Acts in-person exam requirement, which would allow clinicians to prescribe certain addiction treatment medications, like buprenorphine, to new patients through telehealth.
Advocated for legislation that would prohibit states receiving Federal funding for medication-assisted treatment under Medicaid from imposing utilization control policies or procedures (as defined by the Secretary of the Department of Health and Human Services), including prior authorization requirements, with respect to such treatment.
ASAM wrote a letter to the U.S. House Ways and Means Committee regarding the Committees markup of worker and family support and health legislation aimed to expand access to mental health and substance use disorder (SUD) care under Medicare. ASAM requested several, specific clarifications to be made to ensure that Medicare beneficiaries with a primary diagnosis of SUD or with no co-occurring mental health condition can access critical SUD services under Medicare.
ASAM wrote a comment letter to the Centers for Medicare and Medicaid Services (CMS) on the proposed 2023 Medicare Physician Fee Schedule (MPFS) covering revisions to opioid treatment program (OTP) services, a proposal to establish physician payment for the management of chronic pain, and a request for information on intensive outpatient (IOP) services, among other items.
ASAM joined a coalition of public health, medical, and professional organizations in a letter to the Food and Drug Administration (FDA), supporting its intention to issue a proposed rule to reduce the nicotine level in cigarettes to non-addictive or minimally addictive levels.
ASAM joined a letter addressed to Senator Schumer, requesting support of civil
monetary penalty authority for the U.S. Department of Labor (USDOL) to enforce the Paul
Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA).
ASAM joined a letter to Congressional leadership regarding additional investments in the health care workforce, in particular Medicare-supported GME.
ASAM joined a letter to Senate HELP leadership requesting support for funding to enhance the Collaborative Care Model (CoCM), which integrates behavioral health with primary care. Specifically, the letter recommended inclusion of bipartisan language found in Title III, Subtitle A, Section 301 of H.R. 7666 that provides grants to primary care to implement the CoCM.
ASAM joined a letter to HHS, supporting the elevating of the Office of the Assistant Secretary for Preparedness and Response into a separate division, the Administration for Strategic
Preparedness and Response (ASPR) and urging proactive steps to integrate mental health and substance use throughout the operations of ASPR.
ASAM joined a letter to CMS, providing input on the Conditions of Participation for Rural
Emergency Hospitals and recommending that CMS increase access to evidence-based treatment by clarifying in the Conditions of Participation that emergency departments operated by Rural Emergency Hospitals must meet the existing standard of care when treating patients with an opioid use disorder.
ASAM joined a letter to bill sponsors supporting S. 4472, the Health Care Capacity for Pediatric Mental Health Act, which would make investments in mental health and substance use disorder care for kids and teens while providing support to the pediatric health professionals who serve.
Advocated for HR 6279/S 3629 - Opioid Treatment Access Act which would make permanent certain COVID-19 flexibilities allowed to states for unsupervised doses, as well as "time in treatment" regulatory changes and to permit pharmacy dispensing of methadone for opioid use disorder treatment for certain experienced cohorts of prescribers.
Advocated for release of implementation rules regarding the CARES Acts amendment of 42 CFR Part 2 to advance further alignment of 42 CFR Part 2 (Part 2) with the Health Insurance Portability and Accountability Act (HIPAA) for the purposes of treatment, payment, and health care operations (TPO).
Advocated for federal clarification of suspicious order rules to break down perceived and real barriers to buprenorphine access at pharmacies
Advocated for passage of HR 3441/ S 1438 the Opioid Workforce Act/Substance Use Disorder Workforce Act to increase Medicare supported GME slots for addiction medicine, addiction psychiatry, and pain medicine.
Advocated for draft legislative text that would close severe MH/SUD coverage gaps in Medicare.
Advocated for federal agency guidance on CAPTA reporting vs. notification requirements.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA), Office of Natl Drug Control Policy (NDCP), Substance Abuse & Mental Health Services Administration (SAMHSA), Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Advocated for Increased appropriations for HRSAs Substance Use Disorder Treatment and Recovery Loan Repayment Program. This program provides student loan repayment for addiction treatment professionals who commit to working in underserved or high-risk communities.
Advocated for increased appropriations for HRSAs Addiction Medicine Fellowship Program. This program provides grants to institutions with training opportunities for fellows in addiction medicine and addiction psychiatry who have demonstrated interest in providing addiction treatment in underserved communities.
Advocated for S 2235/HR 2067 - Medication Access and Training Expansion (MATE) Act of 2021: This legislation would ensure most Drug Enforcement Agency (DEA) controlled medication prescribers have a baseline knowledge of how to identify, treat, and manage patients with SUD and would allow accredited health professional schools and residency programs to fulfill the training requirement through their own curricula, as well as provide them with resources to do so.
Advocated for simultaneous passage of S 445/HR 1384 - Mainstreaming Addiction Treatment (MAT) Act, which would eliminate the requirement that practitioners apply for a separate waiver through the DEA to prescribe buprenorphine for addiction and eliminate the patient limits on buprenorphine prescribers.
Advocated for S 285/HR 955 - the Medicaid Reentry Act: This legislation would allow for reestablishment of health insurance coverage under Medicaid for eligible individuals who
are incarcerated, during the 30-day period preceding their release from jail or prison.
Advocated for HR 1364/S.4804 - the Parity Enforcement Act: This legislation would expand the U.S. Department of Labors authority to hold health insurers and plan sponsors accountable for offering health plans that violate the Mental Health Parity and Addiction Equity Act (MHPAEA) of 2008 or for employing utilization review processes that prove more restrictive for mental health and addiction care than for other medical care in violation of the MHPAEA.
Advocated for S 340/HR 1674 - TREATS Act: This legislation would make permanent a new, audio-video, telehealth evaluation exception to the Ryan Haight Acts in-person exam requirement, which would allow clinicians to prescribe certain addiction treatment medications, like buprenorphine, to new patients through telehealth.
Advocated for legislation that would prohibit states receiving Federal funding for medication-assisted treatment under Medicaid from imposing utilization control policies or procedures (as defined by the Secretary of the Department of Health and Human Services), including prior authorization requirements, with respect to such treatment.
ASAM wrote a letter to the U.S. House Ways and Means Committee regarding the Committees markup of worker and family support and health legislation aimed to expand access to mental health and substance use disorder (SUD) care under Medicare. ASAM requested several, specific clarifications to be made to ensure that Medicare beneficiaries with a primary diagnosis of SUD or with no co-occurring mental health condition can access critical SUD services under Medicare.
ASAM wrote a comment letter to the Centers for Medicare and Medicaid Services (CMS) on the proposed 2023 Medicare Physician Fee Schedule (MPFS) covering revisions to opioid treatment program (OTP) services, a proposal to establish physician payment for the management of chronic pain, and a request for information on intensive outpatient (IOP) services, among other items.
ASAM joined a coalition of public health, medical, and professional organizations in a letter to the Food and Drug Administration (FDA), supporting its intention to issue a proposed rule to reduce the nicotine level in cigarettes to non-addictive or minimally addictive levels.
ASAM joined a letter addressed to Senator Schumer, requesting support of civil
monetary penalty authority for the U.S. Department of Labor (USDOL) to enforce the Paul
Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA).
ASAM joined a letter to Congressional leadership regarding additional investments in the health care workforce, in particular Medicare-supported GME.
ASAM joined a letter to Senate HELP leadership requesting support for funding to enhance the Collaborative Care Model (CoCM), which integrates behavioral health with primary care. Specifically, the letter recommended inclusion of bipartisan language found in Title III, Subtitle A, Section 301 of H.R. 7666 that provides grants to primary care to implement the CoCM.
ASAM joined a letter to HHS, supporting the elevating of the Office of the Assistant Secretary for Preparedness and Response into a separate division, the Administration for Strategic
Preparedness and Response (ASPR) and urging proactive steps to integrate mental health and substance use throughout the operations of ASPR.
ASAM joined a letter to CMS, providing input on the Conditions of Participation for Rural
Emergency Hospitals and recommending that CMS increase access to evidence-based treatment by clarifying in the Conditions of Participation that emergency departments operated by Rural Emergency Hospitals must meet the existing standard of care when treating patients with an opioid use disorder.
ASAM joined a letter to bill sponsors supporting S. 4472, the Health Care Capacity for Pediatric Mental Health Act, which would make investments in mental health and substance use disorder care for kids and teens while providing support to the pediatric health professionals who serve.
Advocated for HR 6279/S 3629 - Opioid Treatment Access Act which would make permanent certain COVID-19 flexibilities allowed to states for unsupervised doses, as well as "time in treatment" regulatory changes and to permit pharmacy dispensing of methadone for opioid use disorder treatment for certain experienced cohorts of prescribers.
Advocated for release of implementation rules regarding the CARES Acts amendment of 42 CFR Part 2 to advance further alignment of 42 CFR Part 2 (Part 2) with the Health Insurance Portability and Accountability Act (HIPAA) for the purposes of treatment, payment, and health care operations (TPO).
Advocated for federal clarification of suspicious order rules to break down perceived and real barriers to buprenorphine access at pharmacies
Advocated for passage of HR 3441/ S 1438 the Opioid Workforce Act/Substance Use Disorder Workforce Act to increase Medicare supported GME slots for addiction medicine, addiction psychiatry, and pain medicine.
Advocated for draft legislative text that would close severe MH/SUD coverage gaps in Medicare.
Advocated for federal agency guidance on CAPTA reporting vs. notification requirements.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Advocated for Increased appropriations for HRSAs Substance Use Disorder Treatment and Recovery Loan Repayment Program. This program provides student loan repayment for addiction treatment professionals who commit to working in underserved or high-risk communities.
Advocated for increased appropriations for HRSAs Addiction Medicine Fellowship Program. This program provides grants to institutions with training opportunities for fellows in addiction medicine and addiction psychiatry who have demonstrated interest in providing addiction treatment in underserved communities.
Advocated for S 2235/HR 2067 - Medication Access and Training Expansion (MATE) Act of 2021: This legislation would ensure most Drug Enforcement Agency (DEA) controlled medication prescribers have a baseline knowledge of how to identify, treat, and manage patients with SUD and would allow accredited health professional schools and residency programs to fulfill the training requirement through their own curricula, as well as provide them with resources to do so.
Advocated for simultaneous passage of S 445/HR 1384 - Mainstreaming Addiction Treatment (MAT) Act, which would eliminate the requirement that practitioners apply for a separate waiver through the DEA to prescribe buprenorphine for addiction and eliminate the patient limits on buprenorphine prescribers.
Advocated for S 285/HR 955 - the Medicaid Reentry Act: This legislation would allow for reestablishment of health insurance coverage under Medicaid for eligible individuals who
are incarcerated, during the 30-day period preceding their release from jail or prison.
Advocated for HR 1364/S.4804 - the Parity Enforcement Act: This legislation would expand the U.S. Department of Labors authority to hold health insurers and plan sponsors accountable for offering health plans that violate the Mental Health Parity and Addiction Equity Act (MHPAEA) of 2008 or for employing utilization review processes that prove more restrictive for mental health and addiction care than for other medical care in violation of the MHPAEA.
Advocated for S 340/HR 1674 - TREATS Act: This legislation would make permanent a new, audio-video, telehealth evaluation exception to the Ryan Haight Acts in-person exam requirement, which would allow clinicians to prescribe certain addiction treatment medications, like buprenorphine, to new patients through telehealth.
Advocated for legislation that would prohibit states receiving Federal funding for medication-assisted treatment under Medicaid from imposing utilization control policies or procedures (as defined by the Secretary of the Department of Health and Human Services), including prior authorization requirements, with respect to such treatment.
ASAM wrote a letter to the U.S. House Ways and Means Committee regarding the Committees markup of worker and family support and health legislation aimed to expand access to mental health and substance use disorder (SUD) care under Medicare. ASAM requested several, specific clarifications to be made to ensure that Medicare beneficiaries with a primary diagnosis of SUD or with no co-occurring mental health condition can access critical SUD services under Medicare.
ASAM wrote a comment letter to the Centers for Medicare and Medicaid Services (CMS) on the proposed 2023 Medicare Physician Fee Schedule (MPFS) covering revisions to opioid treatment program (OTP) services, a proposal to establish physician payment for the management of chronic pain, and a request for information on intensive outpatient (IOP) services, among other items.
ASAM joined a coalition of public health, medical, and professional organizations in a letter to the Food and Drug Administration (FDA), supporting its intention to issue a proposed rule to reduce the nicotine level in cigarettes to non-addictive or minimally addictive levels.
ASAM joined a letter addressed to Senator Schumer, requesting support of civil
monetary penalty authority for the U.S. Department of Labor (USDOL) to enforce the Paul
Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA).
ASAM joined a letter to Congressional leadership regarding additional investments in the health care workforce, in particular Medicare-supported GME.
ASAM joined a letter to Senate HELP leadership requesting support for funding to enhance the Collaborative Care Model (CoCM), which integrates behavioral health with primary care. Specifically, the letter recommended inclusion of bipartisan language found in Title III, Subtitle A, Section 301 of H.R. 7666 that provides grants to primary care to implement the CoCM.
ASAM joined a letter to HHS, supporting the elevating of the Office of the Assistant Secretary for Preparedness and Response into a separate division, the Administration for Strategic
Preparedness and Response (ASPR) and urging proactive steps to integrate mental health and substance use throughout the operations of ASPR.
ASAM joined a letter to CMS, providing input on the Conditions of Participation for Rural
Emergency Hospitals and recommending that CMS increase access to evidence-based treatment by clarifying in the Conditions of Participation that emergency departments operated by Rural Emergency Hospitals must meet the existing standard of care when treating patients with an opioid use disorder.
ASAM joined a letter to bill sponsors supporting S. 4472, the Health Care Capacity for Pediatric Mental Health Act, which would make investments in mental health and substance use disorder care for kids and teens while providing support to the pediatric health professionals who serve.
Advocated for HR 6279/S 3629 - Opioid Treatment Access Act which would make permanent certain COVID-19 flexibilities allowed to states for unsupervised doses, as well as "time in treatment" regulatory changes and to permit pharmacy dispensing of methadone for opioid use disorder treatment for certain experienced cohorts of prescribers.
Advocated for release of implementation rules regarding the CARES Acts amendment of 42 CFR Part 2 to advance further alignment of 42 CFR Part 2 (Part 2) with the Health Insurance Portability and Accountability Act (HIPAA) for the purposes of treatment, payment, and health care operations (TPO).
Advocated for federal clarification of suspicious order rules to break down perceived and real barriers to buprenorphine access at pharmacies
Advocated for passage of HR 3441/ S 1438 the Opioid Workforce Act/Substance Use Disorder Workforce Act to increase Medicare supported GME slots for addiction medicine, addiction psychiatry, and pain medicine.
Advocated for draft legislative text that would close severe MH/SUD coverage gaps in Medicare.
Advocated for federal agency guidance on CAPTA reporting vs. notification requirements.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Advocated for Increased appropriations for HRSAs Substance Use Disorder Treatment and Recovery Loan Repayment Program. This program provides student loan repayment for addiction treatment professionals who commit to working in underserved or high-risk communities.
Advocated for increased appropriations for HRSAs Addiction Medicine Fellowship Program. This program provides grants to institutions with training opportunities for fellows in addiction medicine and addiction psychiatry who have demonstrated interest in providing addiction treatment in underserved communities.
Advocated for S 2235/HR 2067 - Medication Access and Training Expansion (MATE) Act of 2021: This legislation would ensure most Drug Enforcement Agency (DEA) controlled medication prescribers have a baseline knowledge of how to identify, treat, and manage patients with SUD and would allow accredited health professional schools and residency programs to fulfill the training requirement through their own curricula, as well as provide them with resources to do so.
Advocated for simultaneous passage of S 445/HR 1384 - Mainstreaming Addiction Treatment (MAT) Act, which would eliminate the requirement that practitioners apply for a separate waiver through the DEA to prescribe buprenorphine for addiction and eliminate the patient limits on buprenorphine prescribers.
Advocated for S 285/HR 955 - the Medicaid Reentry Act: This legislation would allow for reestablishment of health insurance coverage under Medicaid for eligible individuals who
are incarcerated, during the 30-day period preceding their release from jail or prison.
Advocated for HR 1364/S.4804 - the Parity Enforcement Act: This legislation would expand the U.S. Department of Labors authority to hold health insurers and plan sponsors accountable for offering health plans that violate the Mental Health Parity and Addiction Equity Act (MHPAEA) of 2008 or for employing utilization review processes that prove more restrictive for mental health and addiction care than for other medical care in violation of the MHPAEA.
Advocated for S 340/HR 1674 - TREATS Act: This legislation would make permanent a new, audio-video, telehealth evaluation exception to the Ryan Haight Acts in-person exam requirement, which would allow clinicians to prescribe certain addiction treatment medications, like buprenorphine, to new patients through telehealth.
Advocated for legislation that would prohibit states receiving Federal funding for medication-assisted treatment under Medicaid from imposing utilization control policies or procedures (as defined by the Secretary of the Department of Health and Human Services), including prior authorization requirements, with respect to such treatment.
ASAM wrote a letter to the U.S. House Ways and Means Committee regarding the Committees markup of worker and family support and health legislation aimed to expand access to mental health and substance use disorder (SUD) care under Medicare. ASAM requested several, specific clarifications to be made to ensure that Medicare beneficiaries with a primary diagnosis of SUD or with no co-occurring mental health condition can access critical SUD services under Medicare.
ASAM wrote a comment letter to the Centers for Medicare and Medicaid Services (CMS) on the proposed 2023 Medicare Physician Fee Schedule (MPFS) covering revisions to opioid treatment program (OTP) services, a proposal to establish physician payment for the management of chronic pain, and a request for information on intensive outpatient (IOP) services, among other items.
ASAM joined a coalition of public health, medical, and professional organizations in a letter to the Food and Drug Administration (FDA), supporting its intention to issue a proposed rule to reduce the nicotine level in cigarettes to non-addictive or minimally addictive levels.
ASAM joined a letter addressed to Senator Schumer, requesting support of civil
monetary penalty authority for the U.S. Department of Labor (USDOL) to enforce the Paul
Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA).
ASAM joined a letter to Congressional leadership regarding additional investments in the health care workforce, in particular Medicare-supported GME.
ASAM joined a letter to Senate HELP leadership requesting support for funding to enhance the Collaborative Care Model (CoCM), which integrates behavioral health with primary care. Specifically, the letter recommended inclusion of bipartisan language found in Title III, Subtitle A, Section 301 of H.R. 7666 that provides grants to primary care to implement the CoCM.
ASAM joined a letter to HHS, supporting the elevating of the Office of the Assistant Secretary for Preparedness and Response into a separate division, the Administration for Strategic
Preparedness and Response (ASPR) and urging proactive steps to integrate mental health and substance use throughout the operations of ASPR.
ASAM joined a letter to CMS, providing input on the Conditions of Participation for Rural
Emergency Hospitals and recommending that CMS increase access to evidence-based treatment by clarifying in the Conditions of Participation that emergency departments operated by Rural Emergency Hospitals must meet the existing standard of care when treating patients with an opioid use disorder.
ASAM joined a letter to bill sponsors supporting S. 4472, the Health Care Capacity for Pediatric Mental Health Act, which would make investments in mental health and substance use disorder care for kids and teens while providing support to the pediatric health professionals who serve.
Advocated for HR 6279/S 3629 - Opioid Treatment Access Act which would make permanent certain COVID-19 flexibilities allowed to states for unsupervised doses, as well as "time in treatment" regulatory changes and to permit pharmacy dispensing of methadone for opioid use disorder treatment for certain experienced cohorts of prescribers.
Advocated for release of implementation rules regarding the CARES Acts amendment of 42 CFR Part 2 to advance further alignment of 42 CFR Part 2 (Part 2) with the Health Insurance Portability and Accountability Act (HIPAA) for the purposes of treatment, payment, and health care operations (TPO).
Advocated for federal clarification of suspicious order rules to break down perceived and real barriers to buprenorphine access at pharmacies
Advocated for passage of HR 3441/ S 1438 the Opioid Workforce Act/Substance Use Disorder Workforce Act to increase Medicare supported GME slots for addiction medicine, addiction psychiatry, and pain medicine.
Advocated for draft legislative text that would close severe MH/SUD coverage gaps in Medicare.
Advocated for federal agency guidance on CAPTA reporting vs. notification requirements.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO), Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Advocated for Increased appropriations for HRSAs Substance Use Disorder Treatment and Recovery Loan Repayment Program. This program provides student loan repayment for addiction treatment professionals who commit to working in underserved or high-risk communities.
Advocated for increased appropriations for HRSAs Addiction Medicine Fellowship Program. This program provides grants to institutions with training opportunities for fellows in addiction medicine and addiction psychiatry who have demonstrated interest in providing addiction treatment in underserved communities.
Advocated for S 2235/HR 2067 - Medication Access and Training Expansion (MATE) Act of 2021: This legislation would ensure most Drug Enforcement Agency (DEA) controlled medication prescribers have a baseline knowledge of how to identify, treat, and manage patients with SUD and would allow accredited health professional schools and residency programs to fulfill the training requirement through their own curricula, as well as provide them with resources to do so.
Advocated for simultaneous passage of S 445/HR 1384 - Mainstreaming Addiction Treatment (MAT) Act, which would eliminate the requirement that practitioners apply for a separate waiver through the DEA to prescribe buprenorphine for addiction and eliminate the patient limits on buprenorphine prescribers.
Advocated for S 285/HR 955 - the Medicaid Reentry Act: This legislation would allow for reestablishment of health insurance coverage under Medicaid for eligible individuals who
are incarcerated, during the 30-day period preceding their release from jail or prison.
Advocated for HR 1364/S.4804 - the Parity Enforcement Act: This legislation would expand the U.S. Department of Labors authority to hold health insurers and plan sponsors accountable for offering health plans that violate the Mental Health Parity and Addiction Equity Act (MHPAEA) of 2008 or for employing utilization review processes that prove more restrictive for mental health and addiction care than for other medical care in violation of the MHPAEA.
Advocated for S 340/HR 1674 - TREATS Act: This legislation would make permanent a new, audio-video, telehealth evaluation exception to the Ryan Haight Acts in-person exam requirement, which would allow clinicians to prescribe certain addiction treatment medications, like buprenorphine, to new patients through telehealth.
Advocated for legislation that would prohibit states receiving Federal funding for medication-assisted treatment under Medicaid from imposing utilization control policies or procedures (as defined by the Secretary of the Department of Health and Human Services), including prior authorization requirements, with respect to such treatment.
ASAM wrote a letter to the U.S. House Ways and Means Committee regarding the Committees markup of worker and family support and health legislation aimed to expand access to mental health and substance use disorder (SUD) care under Medicare. ASAM requested several, specific clarifications to be made to ensure that Medicare beneficiaries with a primary diagnosis of SUD or with no co-occurring mental health condition can access critical SUD services under Medicare.
ASAM wrote a comment letter to the Centers for Medicare and Medicaid Services (CMS) on the proposed 2023 Medicare Physician Fee Schedule (MPFS) covering revisions to opioid treatment program (OTP) services, a proposal to establish physician payment for the management of chronic pain, and a request for information on intensive outpatient (IOP) services, among other items.
ASAM joined a coalition of public health, medical, and professional organizations in a letter to the Food and Drug Administration (FDA), supporting its intention to issue a proposed rule to reduce the nicotine level in cigarettes to non-addictive or minimally addictive levels.
ASAM joined a letter addressed to Senator Schumer, requesting support of civil
monetary penalty authority for the U.S. Department of Labor (USDOL) to enforce the Paul
Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA).
ASAM joined a letter to Congressional leadership regarding additional investments in the health care workforce, in particular Medicare-supported GME.
ASAM joined a letter to Senate HELP leadership requesting support for funding to enhance the Collaborative Care Model (CoCM), which integrates behavioral health with primary care. Specifically, the letter recommended inclusion of bipartisan language found in Title III, Subtitle A, Section 301 of H.R. 7666 that provides grants to primary care to implement the CoCM.
ASAM joined a letter to HHS, supporting the elevating of the Office of the Assistant Secretary for Preparedness and Response into a separate division, the Administration for Strategic
Preparedness and Response (ASPR) and urging proactive steps to integrate mental health and substance use throughout the operations of ASPR.
ASAM joined a letter to CMS, providing input on the Conditions of Participation for Rural
Emergency Hospitals and recommending that CMS increase access to evidence-based treatment by clarifying in the Conditions of Participation that emergency departments operated by Rural Emergency Hospitals must meet the existing standard of care when treating patients with an opioid use disorder.
ASAM joined a letter to bill sponsors supporting S. 4472, the Health Care Capacity for Pediatric Mental Health Act, which would make investments in mental health and substance use disorder care for kids and teens while providing support to the pediatric health professionals who serve.
Advocated for HR 6279/S 3629 - Opioid Treatment Access Act which would make permanent certain COVID-19 flexibilities allowed to states for unsupervised doses, as well as "time in treatment" regulatory changes and to permit pharmacy dispensing of methadone for opioid use disorder treatment for certain experienced cohorts of prescribers.
Advocated for release of implementation rules regarding the CARES Acts amendment of 42 CFR Part 2 to advance further alignment of 42 CFR Part 2 (Part 2) with the Health Insurance Portability and Accountability Act (HIPAA) for the purposes of treatment, payment, and health care operations (TPO).
Advocated for federal clarification of suspicious order rules to break down perceived and real barriers to buprenorphine access at pharmacies
Advocated for passage of HR 3441/ S 1438 the Opioid Workforce Act/Substance Use Disorder Workforce Act to increase Medicare supported GME slots for addiction medicine, addiction psychiatry, and pain medicine.
Advocated for draft legislative text that would close severe MH/SUD coverage gaps in Medicare.
Advocated for federal agency guidance on CAPTA reporting vs. notification requirements.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Substance Abuse & Mental Health Services Administration (SAMHSA), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
Advocated for Increased appropriations for HRSAs Substance Use Disorder Treatment and Recovery Loan Repayment Program. This program provides student loan repayment for addiction treatment professionals who commit to working in underserved or high-risk communities.
Advocated for increased appropriations for HRSAs Addiction Medicine Fellowship Program. This program provides grants to institutions with training opportunities for fellows in addiction medicine and addiction psychiatry who have demonstrated interest in providing addiction treatment in underserved communities.
Advocated for S 2235/HR 2067 - Medication Access and Training Expansion (MATE) Act of 2021: This legislation would ensure most Drug Enforcement Agency (DEA) controlled medication prescribers have a baseline knowledge of how to identify, treat, and manage patients with SUD and would allow accredited health professional schools and residency programs to fulfill the training requirement through their own curricula, as well as provide them with resources to do so.
Advocated for simultaneous passage of S 445/HR 1384 - Mainstreaming Addiction Treatment (MAT) Act, which would eliminate the requirement that practitioners apply for a separate waiver through the DEA to prescribe buprenorphine for addiction and eliminate the patient limits on buprenorphine prescribers.
Advocated for S 285/HR 955 - the Medicaid Reentry Act: This legislation would allow for reestablishment of health insurance coverage under Medicaid for eligible individuals who
are incarcerated, during the 30-day period preceding their release from jail or prison.
Advocated for HR 1364/S.4804 - the Parity Enforcement Act: This legislation would expand the U.S. Department of Labors authority to hold health insurers and plan sponsors accountable for offering health plans that violate the Mental Health Parity and Addiction Equity Act (MHPAEA) of 2008 or for employing utilization review processes that prove more restrictive for mental health and addiction care than for other medical care in violation of the MHPAEA.
Advocated for S 340/HR 1674 - TREATS Act: This legislation would make permanent a new, audio-video, telehealth evaluation exception to the Ryan Haight Acts in-person exam requirement, which would allow clinicians to prescribe certain addiction treatment medications, like buprenorphine, to new patients through telehealth.
Advocated for legislation that would prohibit states receiving Federal funding for medication-assisted treatment under Medicaid from imposing utilization control policies or procedures (as defined by the Secretary of the Department of Health and Human Services), including prior authorization requirements, with respect to such treatment.
ASAM wrote a letter to the U.S. House Ways and Means Committee regarding the Committees markup of worker and family support and health legislation aimed to expand access to mental health and substance use disorder (SUD) care under Medicare. ASAM requested several, specific clarifications to be made to ensure that Medicare beneficiaries with a primary diagnosis of SUD or with no co-occurring mental health condition can access critical SUD services under Medicare.
ASAM wrote a comment letter to the Centers for Medicare and Medicaid Services (CMS) on the proposed 2023 Medicare Physician Fee Schedule (MPFS) covering revisions to opioid treatment program (OTP) services, a proposal to establish physician payment for the management of chronic pain, and a request for information on intensive outpatient (IOP) services, among other items.
ASAM joined a coalition of public health, medical, and professional organizations in a letter to the Food and Drug Administration (FDA), supporting its intention to issue a proposed rule to reduce the nicotine level in cigarettes to non-addictive or minimally addictive levels.
ASAM joined a letter addressed to Senator Schumer, requesting support of civil
monetary penalty authority for the U.S. Department of Labor (USDOL) to enforce the Paul
Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA).
ASAM joined a letter to Congressional leadership regarding additional investments in the health care workforce, in particular Medicare-supported GME.
ASAM joined a letter to Senate HELP leadership requesting support for funding to enhance the Collaborative Care Model (CoCM), which integrates behavioral health with primary care. Specifically, the letter recommended inclusion of bipartisan language found in Title III, Subtitle A, Section 301 of H.R. 7666 that provides grants to primary care to implement the CoCM.
ASAM joined a letter to HHS, supporting the elevating of the Office of the Assistant Secretary for Preparedness and Response into a separate division, the Administration for Strategic
Preparedness and Response (ASPR) and urging proactive steps to integrate mental health and substance use throughout the operations of ASPR.
ASAM joined a letter to CMS, providing input on the Conditions of Participation for Rural
Emergency Hospitals and recommending that CMS increase access to evidence-based treatment by clarifying in the Conditions of Participation that emergency departments operated by Rural Emergency Hospitals must meet the existing standard of care when treating patients with an opioid use disorder.
ASAM joined a letter to bill sponsors supporting S. 4472, the Health Care Capacity for Pediatric Mental Health Act, which would make investments in mental health and substance use disorder care for kids and teens while providing support to the pediatric health professionals who serve.
Advocated for HR 6279/S 3629 - Opioid Treatment Access Act which would make permanent certain COVID-19 flexibilities allowed to states for unsupervised doses, as well as "time in treatment" regulatory changes and to permit pharmacy dispensing of methadone for opioid use disorder treatment for certain experienced cohorts of prescribers.
Advocated for release of implementation rules regarding the CARES Acts amendment of 42 CFR Part 2 to advance further alignment of 42 CFR Part 2 (Part 2) with the Health Insurance Portability and Accountability Act (HIPAA) for the purposes of treatment, payment, and health care operations (TPO).
Advocated for federal clarification of suspicious order rules to break down perceived and real barriers to buprenorphine access at pharmacies
Advocated for passage of HR 3441/ S 1438 the Opioid Workforce Act/Substance Use Disorder Workforce Act to increase Medicare supported GME slots for addiction medicine, addiction psychiatry, and pain medicine.
Advocated for draft legislative text that would close severe MH/SUD coverage gaps in Medicare.
Advocated for federal agency guidance on CAPTA reporting vs. notification requirements.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |